Original Katsura branch rice inner mesh
Great content
On May 10, Buchang Pharmaceutical announced that the racoxamide tablets of Shaanxi Buchang Pharmaceutical, a wholly-owned subsidiary of Shaanxi Buchang Pharmaceutical, were approved for listing, becoming the second domestic company. Racoxamide, a new anti-epileptic drug with global sales of more than $1.6 billion in 2020, was approved in China at the end of 2018 and is in a period of rapid growth.
Lacosamide is a novel N-methyl-D-aspartate (NMDA) receptor glycine site binding antagonist developed by Unspec, which is an anticonvulsant with a completely new dual mechanism of action. Racoxamide tablets are indicated for monotherapy and combination therapy for partial seizures in patients with epilepsy aged 4 years and older.
According to Unisby' financial report, global sales of racoxamide in 2020 were $1.656 billion. In November 2018, Unisby's Laroxamide tablets were approved for listing in China, and the market is in a period of rapid rise.
Sales of racoxamide terminals in urban physical pharmacies in China
Source: Intranet China's urban physical pharmacy terminal competition pattern
According to intranet data, in 2020, the sales of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals totaled 37.76 million yuan. Due to the small base, the sales of racoxamide terminals in urban physical pharmacies in China rose by 981.89% in 2020, an obvious increase.
Racoxamide tablets listing application for approval enterprises
Source: Intranet one-click search
Buchang Pharmaceutical's racoxamide tablets are the second domestic one. In January 2019, Jiangxi Qingfeng Pharmaceutical won the first domestic imitation of Racoxamide tablets. On April 15, 2021, hefei Yifan Biotechnology submitted a four-category application for imitation of cosamide tablets, which was undertaken by CDE. In addition, the imitation applications of lacoxamide tablets of 6 enterprises, including CSPC Pharmaceutical Group, Changzhou Pharmaceutical, Shandong Bainuo Pharmaceutical, Shijiazhuang Siyao, Beijing Sihuan Pharmaceutical, and Hefei Yingtai Pharmaceutical, are under review.
Source: Intranet database, company announcements
Note: The China Urban Physical Pharmacy Terminal Competition Pattern Database of MinneiNet is an enlarged version of the urban physical pharmacy database covering 293 urban physical pharmacies in prefectures and cities and above (excluding county and rural physical pharmacies) across the country and continuously monitoring all categories. The above sales are calculated based on the average retail price of the product at the terminal.